#United States #Las Vegas #Cervical Cancer #Noul #miLab CER

Noul Unveils miLab™ CER at CES 2026: A Game Changer for Women’s Health

In a significant advancement for women’s healthcare, Noul Co., Ltd. has announced the launch of its AI-powered cervical cancer diagnostic solution, miLab™ CER, during CES 2026 in Las Vegas. Noul, a leader in AI-driven diagnostics, aims to tackle one of the most pressing barriers in women's health: access to timely cervical cancer screening.

The escalating global cervical cancer crisis is primarily attributed to healthcare infrastructure deficiencies, which disproportionately affect women in various regions. With cervical cancer accounting for approximately 660,000 new diagnoses and 350,000 deaths annually worldwide, Noul’s initiative is both timely and essential. The World Health Organization's goal to increase cervical cancer screening to 70% by 2030 underscores the urgent need for innovative solutions.

A User-Friendly Solution for Complex Diagnostics

miLab™ CER revolutionizes the diagnostic workflow by automating all processes involved in cervical cancer screening. Traditionally, this labor-intensive task relied heavily on skilled personnel and centralized facilities, often resulting in delays and suboptimal access. Noul’s diagnostic tool cuts down workflow time by 80%, providing results in under 20 minutes within a single compact device.

The process includes crucial steps from slide staining to digital imaging and AI-based analysis, all automated within the miLab CER unit. This integration significantly reduces the complexity of cervical cancer diagnosis, enabling consistent, high-quality results, particularly in resource-limited settings.

Sustainability Meets Innovation

In addition to enhancing access, Noul's solution is environmentally friendly. miLab CER implements Next Generation Staining and Immunostaining (NGSI) technology, which eliminates harmful methanol use, conserves reagents, and drastically reduces wastewater production. During trials, the device achieved 93.9% sensitivity and 97.8% specificity, qualities that match conventional expert evaluations, thus reinforcing its viability as a diagnostic tool.

Shaping the Future of Health Equity

David Lim, CEO of Noul, emphasizes the technology's potential at CES 2026, stating, “miLab CER was developed to address disparities in women's health caused by uneven healthcare access. By enabling consistent cervical cancer diagnostics anywhere in the world, we aim to advance global health equity.”

The company’s commitment to bridging the healthcare access gap is globally recognized, as miLab CER was recommended for use by Unitaid in 2024, thereby positioning it alongside solutions from leading diagnostics firms such as Roche and Hologic. Moving forward, Noul aims to expand its AI diagnostic technologies to cover more disease areas, thereby continuing its mission to bolster healthcare access and equity across the board.

In conclusion, Noul's introduction of miLab CER at CES 2026 marks a pivotal moment in women's health diagnostics. By enhancing efficiency, sustainability, and accessibility, it stands as a beacon of hope in the fight against cervical cancer. This innovative technology not only showcases the power of AI in transforming healthcare delivery but also sets a precedent for future advancements aimed at improving global health for women everywhere.